Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2022-08-18 · accession 0001628280-26-014324 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2022-08-18+ | ARQT | Burnett Patrick | See Remarks | A - Grant | $0.00 | +46.8K | 127.4K | +58% | $0 |
| DM | 2026-03-03 | 2026-03-02 | ARQT | Burnett Patrick | See Remarks | S - Sale | $25.18 | -6,287 | 121.2K | -5% | -$158.3K |
| D | 2026-03-03 | 2026-02-27 | ARQT | Burnett Patrick | See Remarks | A - Grant | $0.00 | +77.0K | 77.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-18 | A | A | 16,750 | $0.00 | 97,401 | D | — | — | (F2) Reflects holdings following the August 18, 2022 transaction reported herein. |
| 2 | Common | Common Stock | 2026-02-27 | A | A | 30,000 | $0.00 | 127,401 | D | — | — | |
| 3 | Common | Common Stock | 2026-03-02 | S | D | 6,106 | $25.16 | 121,295 | D | — | — | (F5) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-03-02 | S | D | 181 | $25.91 | 121,150 | D | — | — | (F6) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.71 to $26.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F7) Due to a scrivener's error on the Reporting Person's Form 4s filed since November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadvertently understated the Reporting Person's ownership by a range of 18 to 36 shares. The corrected number of shares beneficially owned is reflected in this Form 4. |
| 5 | Derivative | Stock Option (right to buy) | 2026-02-27 | A | A | 77,000 | $0.00 | 77,000 | D | $26.97 · — to 2036-02-27 | 77,000 Common Stock | (F8) 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |